Nile Therapeutics, Inc. Announces Dosing of First Patient in Phase 2 Study of CD-NP for the Treatment of Acute Heart Failure
SAN FRANCISCO, Aug. 4 /PRNewswire-FirstCall/ -- Nile Therapeutics, Inc. (Nasdaq: NLTX ), a company focused on the development of novel therapeutics for heart
failure patients, today announced dosing of its first patient in a Phase 2 clinical study of its lead product, CD-NP, for the treatme...
Palatin Technologies, Inc. Receives U.S. Patent Allowance for Heart Failure Drug Candidate
CRANBURY, N.J., Aug. 4 /PRNewswire-FirstCall/ -- Palatin Technologies, Inc. (NYSE Amex: PTN ) announced today that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for its U.S. Patent Application Number 11/694,260, titled "Cyclic Natriuretic Peptide Constructs...
United States FDA Clears the REGEN Trial to Test Bioheart's Combination Gene and Stem Cell Therapy in Heart Failure Patients
SUNRISE, Fla., July 28 /PRNewswire-FirstCall/ -- Bioheart, Inc., (OTC Bulletin Board: BHRT) a company committed to delivering intelligent devices and biologics that help monitor, diagnose and treat heart
failure and cardiovascular diseases announced today that the US FDA cleared a p...
Galichia Heart Hospital Partners with Mobile Surgery International to Develop Wichita-based Center of Excellence with Global Convenience(TM)
Partnership will offer expanded access to choice, quality and cost-efficiency for patients and payers
WICHITA, Kan. and AVENTURA, Fla., June 24 /PRNewswire/ -- Galichia Heart
Hospital and Mobile Surgery International (MSI) have reached an agreement for Galichia to host MSI-coordinated, highly...
Scientists identify gene vital to early embryonic cells forming a normal heart and skull
New research from Cincinnati Children's Hospital Medical Center highlights the critical role a certain gene and its protein play during early embryonic development on formation of a normal heart
In a study posted online June 15 by the Proceedings of the National Academy of Sciences ...
Berlin Heart Inc. Receives FDA Orphan Product Development Grant
THE WOODLANDS, Texas, June 17 /PRNewswire/ -- Berlin Heart
announced it has been awarded an Orphan Product Development Grant by the FDA,
to support the ongoing Investigational Device Exemption (IDE) study of the
EXCOR(R) Pediatric Ventricular Assist Device (VAD). Dr. Christopher Alm...
PeriCor Therapeutics Reports Positive Preclinical Results of GP531 at the European Heart Failure Congress in Nice
Adenosine Regulation with GP531 Improves the Heart's Pumping Function in Dogs with Advanced Chronic Heart
NEW YORK, June 3 /PRNewswire/ -- PeriCor Therapeutics, Inc. announced today that positive preclinical results of its novel cardioprotective agent, GP531, were reported in a poster...
500th Patient Receives Berlin Heart EXCOR Pediatric Ventricular Assist Device
BERLIN, May 28 /PRNewswire/ -- The 500th patient was supported with the
EXCOR(R) Pediatric Ventricular Assist Device (also known as the
"Berlin Heart") since the first implantation of the device in 1990. The
patient, an 11-month-old girl, received the device at the Children's Memo...
Multiple Types of Heart Attacks Reduced by Prasugrel in TRITON-TIMI 38 Trial
Universal Definition of Myocardial Infarction provided jointly by leading international cardiology societies
TOKYO and INDIANAPOLIS, May 21 /PRNewswire-FirstCall/ -- Investigators from the Phase III TRITON-TIMI 38 study applied the new classification system for the Universal Definition of Myo...
Nile Therapeutics CD-NP Clinical Program for Acute Heart Failure Released From Clinical Hold by FDA
SAN FRANCISCO, May 15 /PRNewswire-FirstCall/ -- Nile Therapeutics, Inc. (Nasdaq: NLTX ), a company focused on the development of novel therapeutics for heart
failure patients, received notification from the U.S. Food and Drug Administration (FDA) that the agency has released the Company's CD-N...
Boston Scientific Announces Company Schedule for Heart Rhythm Society Scientific Sessions
NATICK, Mass., May 11 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX ) today announced the schedule of the Company's major events and news announcements at the 30th Annual Scientific Sessions of the Heart
Rhythm Society, which run from May 13 to 16 in Boston. Highlights of t...
deCODE and Celera Partner to Expand use of deCODE Risk Markers for Heart Attack, Stroke and Diabetes
REYKJAVIK, Iceland, and ALAMEDA, California, April 23
/PRNewswire-FirstCall/ -- deCODE genetics (NASDAQ: DCGN ) and Celera
Corporation (NASDAQ: CRA ) today announced the signing of agreements under
which deCODE has granted Celera non-exclusive worldwide licenses to deCODE's
genetic markers f...
Symphony Medical Announces First Patient Successfully Treated With Novel Congestive Heart Failure Therapy
European Trials Commencing for Injectable Biopolymer to Repair Weakened Heart
LAGUNA HILLS, Calif., April 14 /PRNewswire/ -- Symphony Medical, Inc., a developer of novel biopolymer therapies to cardiac abnormalities, announced today that its patented flagship technology, Algisyl-LVR(R), ...
The Journal of Cardiac Failure Publishes Results From Celladon Corporation's First-in-Human Phase 1/2 Clinical Trial in Advanced Heart Failure
Calcium Upregulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID Trial) Demonstrated Safety and Biological Effects of SERCA2a Enzyme Replacement Using Gene Transfer
SAN DIEGO, April 8 /PRNewswire/ -- Celladon Corporation today announced the publication of results ...
Heart Hospital of Austin First Site in World to Test Efficacy of New Adult Stem Cell Therapy to Treat Damaged Heart Tissue in Phase II Trial
Central Texas man receives groundbreaking therapy days after heart
AUSTIN, Texas, March 31 /PRNewswire/ -- On March 30, the Heart
Hospital of Austin treated the first patient in the world enrolled in a groundbreaking Phase II study designed to test the effectiveness and safety of a...
Amorcyte Reports Phase I Results of AMR-001 to Improve Recovery From Severe Heart Attack at ACC Annual Scientific Session
- First Stem Cell Trial to Show Dose-related Significant Improvement in Perfusion -
ORLANDO, Fla., March 30 /PRNewswire/ -- Amorcyte, Inc. (Amorcyte) today announced data from its Phase I clinical trial of AMR-001, the company's lead product for the treatment of damaged heart
New Discoveries on a Fingertip Test for Screening Silent Heart Disease Promising Results of Recent Clinical Studies to be Presented during the 2009 American College of Cardiology Conference, March 29th - April 1st in Orlando
Results of five clinical studies evaluating the predictive value of VENDYS®, the new FDA-approved cardiovascular test, will be presented at the 2009 Annual Scientific Sessions of the American College of Cardiology in Orlando, Florida. The studies, amazingly, show that a simple, inexpensive te...
Nile Therapeutics Provides Update on Phase II CD-NP Clinical Trial for Acute Heart Failure
SAN FRANCISCO, March 27 /PRNewswire-FirstCall/ -- Nile Therapeutics, Inc. (Nasdaq: NLTX ), a leading company in the development of novel therapeutics for heart
failure patients, announced today that, in the course of reviewing the Investigational New Drug (IND) application materials that Nile ...
Atherotech Announces Addition of ApoAI Heart Disease, Diabetes Risk Marker to VAP(R) Test
ApoAI and apoB/apoAI ratio now available with VAP Cholesterol Test at no additional cost
BIRMINGHAM, Ala., March 10 /PRNewswire/ -- Atherotech, Inc., a cardio-diagnostic company, today announced the addition of apolipoprotein A (apoAI) to its VAP(R) Cholesterol Test. The VAP (Vertical Auto Pr...
VAP Test Demonstrates Value of Fish Oil in Reducing Heart Risk for Super Bowl Champs
Advanced cholesterol test helps usher in new era of specialized test for cardiac risk assessment
BIRMINGHAM, Ala., Feb. 19 /PRNewswire/ -- For the Pittsburgh Steelers, adding a heart-healthy supplement to their diet may have given them the boost to win Super Bowl XLIII. That's according t...
KanekaQH(TM) Ubiquinol Dramatically Boosts Ejection Fraction in Patients With Late-Stage Congestive Heart Failure
Results of first clinical trial indicate pre-converted form of Coenzyme Q10 positively impacted heart
function in critically ill subjects
HOUSTON, Feb. 18 /PRNewswire/ -- Results from the first clinical trial evaluating ubiquinol's effects on late-stage congestive heart
failure showed that th...
VAP Cholesterol Test Helps In Search For New Heart Disease Drugs
Peer-reviewed journal, Science, reports that advanced cholesterol test aids in identifying connection between improved lipid profile and heart
BIRMINGHAM, Ala., Feb. 16 /PRNewswire/ -- Using the VAP Cholesterol Test from Atherotech, Inc., University of Maryland researchers h...
Cordex Pharma Forms Heart Failure Medical Advisory Board
Dr. Joshua Hare to Chair the Board
LA JOLLA, Calif., Feb. 11 /PRNewswire-FirstCall/ -- Cordex Pharma, Inc. (OTC Bulletin Board: CDXP) announced today the formation of a Medical Advisory Board to provide clinical guidance for the Company's development program of CDP-1050 for the treatment of ...
Multinational deCODE Study Identifies New Link Between Inflammation and Heart Attack
REYKJAVIK, Iceland, February 9 /PRNewswire-FirstCall/ -- In a paper
published today, scientists at deCODE genetics (Nasdaq: DCGN ) and academic
colleagues from four continents present a novel insight into the connection
between inflammation and heart
disease. Through a genome-wide search in s...
BioIQ Supports American Heart Month to Raise Awareness About Heart Disease, the #1 Killer of Women
Discounted Cholesterol Test Kits Help Women Detect Serious Health Problems While Making Charitable Donations
SANTA BARBARA, Calif., Feb. 6 /PRNewswire/ -- Yes, the truth sometimes hurts. But when it comes to women's health, it's better to face the facts: one in four women in the United States...
Traditional Risk Factors Often Miss Heart Disease Warning Signs
VAP(R) Cholesterol Test helps physicians identify emerging risk factors better than standard cholesterol test and traditional risk factors, study shows
BIRMINGHAM, Ala., Jan. 30 /PRNewswire/ -- Traditional risk factors such as age, standard cholesterol levels and blood pressure do a poor jo...
New Multi-Center Study Finds Masimo SET Pulse Oximetry Screening Significantly Improves Detection of Congenital Heart Disease in Newborns
Study Published in British Medical Journal Indicates Masimo SET May Also Reduce the Need for Pre-Operative Neonatal Intensive Care and Prevent Long-term Neurological Morbidity
IRVINE, Calif., Jan. 30 /PRNewswire-FirstCall/ -- Masimo (Nasdaq: MASI ), the inventor of Pulse CO-Oximetry and...
Nile Therapeutics Announces Focus on CD-NP for Acute Heart Failure and Termination of 2NTX-99 Program
SAN FRANCISCO, Jan. 20 /PRNewswire-FirstCall/ -- Nile Therapeutics, Inc. (Nasdaq: NLTX ), today announced that it will focus resources on the development of its natriuretic peptide franchise, including CD-NP which is in Phase II development for acute heart
failure, and CU-NP which is a pre-clini...
Nile Therapeutics Announces Positive Results from Phase 1b Safety and Pharmacodynamics Study of CD-NP in Patients with Heart Failure
SAN FRANCISCO, Dec. 9 /PRNewswire-FirstCall/ -- Nile Therapeutics, Inc. (Nasdaq: NLTX ), today announced preliminary data from its recently completed multi-center, open-label, ascending-dose Phase 1b clinical study of CD-NP, a novel chimeric natriuretic peptide, in patients with heart
Terumo Heart Announces Appointment of William Pinon to Chief Executive Officer and President
ANN ARBOR, Mich., Nov. 24 /PRNewswire/ -- Terumo Heart, Inc. is pleased to
announce the appointment of William Pinon to the position of Chief Executive
Officer (C.E.O.) and President, effective immediately. "With its innovative
mag-lev technology, Terumo Heart
is positioned for a strong leadership...
CVBT Closes Clinical Development Agreement for Coronary Heart Disease Drug Candidate
LAS VEGAS, Nov. 13 /PRNewswire-FirstCall/ -- CardioVascular
BioTherapeutics, Inc. (OTC Bulletin Board: CVBT) (the "Company") has
entered into its first clinical development agreement for its Coronary
Heart Disease drug candidate with Cardio Neo-Genesis, LP ("CNG"). The
agreement, dated Novembe...
Arizona Heart Innovative Technologies Licenses New Endovascular Device
PHOENIX, Nov. 12 /PRNewswire/ -- Arizona Heart
LLC (AHIT) announced the license of a new medical device for endovascular
use to a publicly traded medical device company. "This is the second
AHIT-developed product that we have licensed in the past ten months. We
Major Independent Study Underscores Utility of deCODE MI(TM) for Better Predicting Risk of Heart Attack, Informing Statin Therapy
REYKJAVIK, Iceland, Nov. 11 /PRNewswire-FirstCall/ -- In a presentation
today at the American Heart
Association Scientific Sessions 2008,
clinicians and researchers from Baylor College of Medicine have presented
data from the Atherosclerosis Risk in Communities (ARIC) study,
Anthera's Varespladib Demonstrates Significant Anti-Inflammatory Effect and LDL Reduction in Patients With Coronary Heart Disease
HAYWARD, Calif., Nov. 11 /PRNewswire/ -- Anthera Pharmaceuticals, Inc.,
a privately held biopharmaceutical company developing anti-inflammatory
drugs, today announced new data on its lead product, varespladib (A-002) at
the American Heart
Association (AHA) Annual Conference in New Orleans,
BSP Signs Agreement With CMP Trading for Distribution of HyperQ(TM) Stress System, for Early Detection of Ischemic Heart Disease, in South Korea
CMP Will Purchase at Least 227 HyperQ(TM) Systems During the Term of the Agreement
TEL AVIV, Israel, November 10 /PRNewswire-FirstCall/ -- BSP (Biological
Signal Processing Ltd.) ( http://www.bsp.co.il/ ), an Israeli company that
develops and markets innovative sy...
Interim Analysis of Top-Line Data From Phase II/III Study Shows Favorable Efficacy & Safety for Corthera's Relaxin in Acute Heart Failure
SAN MATEO‚ Calif.‚ Nov. 10 /PRNewswire/ -- Corthera Inc. today
announced that an interim analysis of top-line data from Pre-RELAX-AHF, the
Phase II portion of a Phase II/III multicenter, randomized, double-blind,
international study, showed favorable efficacy and safety for relaxin, the
Synvista Therapeutics Announces Availability of Haptoglobin Genotyping Technology at The Annual Scientific Sessions of the American Heart Association
New Data Presented at the Meeting Report the Use of Haptoglobin Typing
to Predict Cardiovascular Risk, and Benefit From Tight Glycemic Control in
MONTVALE, N.J., Nov. 10 /PRNewswire-FirstCall/ -- Synvista
Therapeutics, Inc. (Amex: SYI ) today announced at the Annual Scientific
Unique New Initiative by World-Recognized Specialists in Heart Disease and Diabetes to Reduce Residual Vascular Risk Launched Today
NEW ORLEANS and LOS ANGELES, November 10 /PRNewswire/ --
- Current Treatment Fails to Abolish Majority of Vascular Risk
- Residual Risk Reduction Initiative (R3i) Calls for Action to Reduce
the Lipid-Related Residual Vascular Risk Unaddressed by Current Standards
of Care in Millions of Pat...
Atherotech to Exhibit VAP(R) Cholesterol Test at American Heart Association Scientific Sessions 2008
Atherotech to add new apoA1 measurement and apoB:apoA1 ratio to its
comprehensive cholesterol test, further identifying patients at risk of heart
BIRMINGHAM, Ala., Nov. 6 /PRNewswire/ -- Atherotech, Inc., a
cardio-diagnostic company, today announced it w...
Top-Line Preliminary Data From Phase II/III Study of Corthera's Relaxin in Acute Heart Failure to be Presented in Satellite Symposium at AHA Scientific Sessions 2008
SAN MATEO, Calif., Nov. 3 /PRNewswire/ -- Top-line preliminary data
from a Phase II/III clinical trial of Corthera's investigational drug
relaxin for the treatment of acute heart
failure will be presented next
week at a satellite symposium at the American Heart